Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress taking place this week in Edinburgh, UK (October 11-14, 2022).

“Our presentations at ESGCT highlight both uniQure’s exciting pipeline of gene therapy candidates and our leading gene therapy manufacturing and administration capabilities,” stated Ricardo Dolmetsch, president of research & development at uniQure. “We look forward to sharing new preclinical data from our temporal lobe epilepsy (TLE), Alzheimer’s and ALS research programs, as well as highlighting advances with our enabling technologies and manufacturing capabilities.”

Specific details on uniQure’s poster presentations at ESGCT include:

  • Title: Enhancing efficacy and specificity of rAAV5 via small, intermediate, and large peptide insertions
    Date and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BST
    Poster Number: P053
  • Title: Overexpressing a protective variant while simultaneously lowering toxic APOE as potential treatment for Alzheimer Disease
    Date and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BST
    Poster Number: P179
  • Title: Biodistribution and safety of a novel AAV9 gene therapy for treatment of temporal lobe epilepsy shown in non-human primates
    Date and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BST
    Poster Number: P195
  • Title: Scale-down of AAV production from commercial scale to a high-throughput mini-bioreactor system
    Date and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BST
    Poster Number: P327
  • Title: linQURETM platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders
    Date and Time: Thursday, October 13, 2022, 5:30-7:15 p.m. BST
    Poster Number: P076
  • Title: AAV-miQURE®-mediated targeting of hexanucleotide repeat expansion-containing transcripts in ALS C9orf72 mouse models
    Date and Time: Thursday, October 13, 2022, 5:30-7:15 p.m. BST
    Poster Number: P178
  • Title: Development of a novel AAV9 gene therapy for the treatment of temporal lobe epilepsy using animal model and human organotypic slices
    Date and Time: Thursday, October 13, 2022, 5:30-7:15 p.m. BST
    Poster Number: P218
  • Title: Impact of bioreactor control parameters on AAV production
    Date and Time: Thursday, October 13, 2022, 5:30-7:15 p.m. BST
    Poster Number: P346

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:                                                            

FOR INVESTORS:   FOR MEDIA:
Maria E. CantorChiara RussoTom Malone
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
Mobile: 617-680-9452Mobile: 617-306-9137Mobile:339-223-8541
m.cantor@uniQure.comc.russo@uniQure.comt.malone@uniQure.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.